Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165,947 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.
Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H. Yan Y, et al. Among authors: chen j, chen y. EMBO Mol Med. 2018 Apr;10(4):e8478. doi: 10.15252/emmm.201708478. EMBO Mol Med. 2018. PMID: 29523594 Free PMC article.
Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, Yang Y, Wu D, He Y, Zhang J, Lu D, Liu X, Yu L, Zhao S, Li Y, Lin D, Wang Y, Wang L, Chen Y, Sun Y, Wang C, Huang H. Zhang P, et al. Among authors: chen y. Nat Med. 2017 Sep;23(9):1055-1062. doi: 10.1038/nm.4379. Epub 2017 Aug 14. Nat Med. 2017. PMID: 28805822 Free PMC article.
ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. Clegg NJ, et al. Among authors: chen y. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266222 Free PMC article.
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. Liu B, et al. Among authors: chen y. Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439587 Free PMC article.
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.
Chakraborty G, Armenia J, Mazzu YZ, Nandakumar S, Stopsack KH, Atiq MO, Komura K, Jehane L, Hirani R, Chadalavada K, Yoshikawa Y, Khan NA, Chen Y, Abida W, Mucci LA, Lee GM, Nanjangud GJ, Kantoff PW. Chakraborty G, et al. Among authors: chen y. Clin Cancer Res. 2020 Apr 15;26(8):2047-2064. doi: 10.1158/1078-0432.CCR-19-1570. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796516 Free PMC article.
Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Lee YS, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS. Mao N, et al. Among authors: chen y. Cancer Res. 2020 Apr 1;80(7):1428-1437. doi: 10.1158/0008-5472.CAN-19-1394. Epub 2020 Feb 3. Cancer Res. 2020. PMID: 32015092 Free PMC article.
165,947 results
You have reached the last available page of results. Please see the User Guide for more information.